Ads
related to: localized tenosynovial tumor disease- Identify Patients
Get Information on How to Identify
Patients for this TGCT Treatment.
- TGCT Treatment Option
Discover a Prescription Treatment
For Eligible Patients with TGCT.
- GCT-TS Education
Learn More About Tenosynovial Giant
Cell Tumor. Get Information Here.
- Access & Savings
See How You Can Access This TGCT
Treatment for Eligible Patients.
- Dosing Recommendations
Get Dosing Recommendations for
Your TGCT Diagnosed Patients.
- View Safety Info
TGCT Treatment Safety Information
for Healthcare Providers.
- Identify Patients
Search results
Results From The WOW.Com Content Network
Tenosynovial giant cell tumor (TGCT) is a non-malignant tumor defined histologically as inclusions of “osteoclast-like” multinucleated giant cells, hemosiderin, and macrophages. [1] This histology can present one of 2 clinically distinct ways. TGCT tumors often develop from the lining of joints (also known as synovial tissue).
Giant-cell tumor of the tendon sheath, also known as giant-cell synovioma, localized nodular tenosynovitis and localized tenosynovial giant cell tumor or TGCT [1] is a firm lesion, measuring 1 to 3 cm in diameter, and is most commonly attached to the tendons of the fingers, hands, and wrists, with a predilection for the flexor surfaces.
Villonodular synovitis is a type of synovial swelling.. Types include: Pigmented villonodular synovitis; Giant cell tumor of the tendon sheath; Though they have very different names, they have the same histology, and stain positive for CD68, HAM56, and vimentin. [1]
The U.S. Food and Drug Administration on Friday approved Daiichi Sankyo Co Ltd's treatment for adult patients with a type of rare, non-cancerous tumor affecting joints and limbs. The decision ...
This is a shortened version of the thirteenth chapter of the ICD-9: Diseases of the Musculoskeletal System and Connective Tissue. It covers ICD codes 710 to 739 . The full chapter can be found on pages 395 to 415 of Volume 1, which contains all (sub)categories of the ICD-9.
In December 2023, Abbisko Therapeutics entered into a licensing agreement for pimicotinib in all indications for China rights with Merck KGaA. [2] [3] [4]In April 2023, a global phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial designed to evaluate the safety and efficacy of pimicotinib in patients with tenosynovial giant cell tumor was started (NCT05804045).
Pexidartinib, sold under the brand name Turalio, is a kinase inhibitor drug for the treatment of adults with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.
Vimseltinib is an investigational new drug that is being evaluated to treat tenosynovial giant cell tumor. [1] It is a macrophage colony-stimulating factor receptor antagonist. [ 2 ]
Ad
related to: localized tenosynovial tumor disease